



With more than **17 million doses** administered to horses, Boehringer Ingelheim Animal Health has **significant experience in vaccine development and production.**

CONTINUED VACCINE INNOVATION



2003

BI introduces Calvenza® EIV/EHV vaccine portfolio



2007

BI updates EIV per OIE/WHO recommendations



2009

BI introduces updated WNV vaccine strain



2010

Vetera® vaccine portfolio, including Vetera® Gold



2013

BI updates EIV per OIE/WHO recommendations

CURRENT:

Boehringer Ingelheim Animal Health continually monitors current diseases to help ensure your horse is protected against the most current strains.

CONVENIENT:

Vaccines are available as single antigens or in combination with other antigens to conveniently provide protection for your horses.

CUTTING EDGE:

Inclusion of Ultrafil® Purification Technology filters extraneous proteins to help minimize injection-site reactions. Carbimmune® is a proprietary carboxypolymer adjuvant that is used to allow a dual-phase antigen presentation, which elicits high levels of humoral antibody and cellular immunity.

BOEHRINGER INGELHEIM VACCINE ASSURANCE PROGRAM

TECHNICAL SERVICE
1-888-637-4251
PET & EQUINE
(OPT 1 THEN OPT 4)

When you vaccinate your horse, you want to know it will be protected against disease. When your veterinarian administers a Boehringer Ingelheim vaccine to your horse, under the Terms and Conditions of the Boehringer Ingelheim Vaccine Assurance Program, you have the peace of mind that comes from knowing your horse will be covered by the assurance program against the disease the vaccine was designed to protect against.

THE FOLLOWING DISEASES ARE INCLUDED IN THE BOEHRINGER INGELHEIM ASSURANCE PROGRAM:



EQUINE INFLUENZA

One of the most widespread infectious viral equine diseases in the world, equine influenza poses a greater risk to horses that travel and are commingled with other horses.

| PROTECTION ASSURED WITH: | | | |
|---------------------------|-------------------------------|-------------------------|----------------------------------|
| Calvenza®-03 EIV/EHV | Vetera® 2 ^{XP} | Vetera® 5 ^{XP} | Vetera® Gold ^{xP} |
| Vetera® EIV ^{XP} | Vetera® 4 ^{XP} + WNV | Vetera® 6 ^{XP} | Vetera® Gold ^{xP} + VEE |

EQUINE HERPESVIRUS (EHV-1 & EHV-4)

Equine herpesvirus (EHV-1 & EHV-4)* causes infectious respiratory disease, primarily in younger horses.

| PROTECTION ASSURED WITH | OTECTION ASSURED WITH: | | |
|--------------------------------|-----------------------------------|--------------------------|-----------------------------|
| Calvenza®-03 EIV/EHV* | Vetera® 2 ^{XP*} | Vetera® 5 ^{XP*} | Vetera® Gold ^{XP*} |
| Vetera® EHV ^{XP} 1/4* | Vetera® Gold ^{XP} + VEE* | Vetera® 6 ^{XP*} | Rhinomune ^{®**} |

^{*}Boehringer Ingelheim Assurance Program covers respiratory form of EHV-1 & EHV-4.

EASTERN, WESTERN & VENEZUELAN EQUINE ENCEPHALOMYELITIS

EEE, WEE and VEE are mosquito-born diseases that may cause encephalomyelitis in horse.

| PROTECTION ASSURED WITH: | |
|-------------------------------|---|
| Vetera® EWT | Vetera® 5 ^{XP} |
| Vetera® VEWT† | Vetera® 6 ^{XP†} |
| Vetera® EWT + WNV | Vetera [®] Gold ^{xp} |
| Vetera® VEWT + WNV† | Vetera [®] Gold ^{xP} + VEE [†] |
| Vetera® 4 ^{XP} + WNV | |

[†]These SKUs provide protection against VEE.

TETANUS

Usually considered a soilborne organism, this disease is caused by a specific neurotoxin, tetanospasms in the horse.

| PROTECTION ASSURED WITH: | |
|-------------------------------|--|
| Vetera® EWT | Vetera® 5 ^{XP} |
| Vetera® VEWT | Vetera® 6 ^{XP} |
| Vetera® EWT + WNV | Vetera [®] Gold ^{XP} |
| Vetera® VEWT + WNV | Vetera® Gold ^{XP} + VEE |
| Vetera® 4 ^{XP} + WNV | Tetguard [®] |

WEST NILE VIRUS

This mosquito-borne virus is considered endemic within the United States, and may cause encephalomyelitis.

| PROTECTION ASSURED WITH: | |
|--------------------------|--|
| Vetera® WNV | Vetera® 4XP + WNV |
| Vetera® EWT + WNV | Vetera [®] Gold ^{xp} |
| Vetera® VEWT + WNV | Vetera® Gold ^{XP} + VEE |

RABIES

Exposure to rabies occurs through infected animal bites.

| PROTECTION ASSURED WITH: |
|--------------------------|
| Imrab® Large Animal |

^{**}For protection against EHV-1 respiratory disease.

Terms and Conditions

- Boehringer Ingelheim Animal Health equine vaccines must have been administered by a licensed veterinarian with a valid veterinarian-client-patient relationship, as defined by the AVMA in CPG 7125.06.
- Veterinarians must communicate with Boehringer Ingelheim Veterinary Technical Services (888-637-4251, option 1, option 4) when determining a diagnostic and treatment procedure.
- All previously naive unvaccinated horses, when vaccinated according to label directions, will be covered by the Boehringer Ingelheim Vaccine Assurance Program against the disease(s) specified within this document when the Boehringer equine vaccine corresponding to the specified disease. (See included charts for diseases corresponding with covered diseases.)
- Previously vaccinated horses vaccinated within the previous 12 months must be vaccinated by a licensed veterinarian.
 Proof of vaccination must be provided for the covered disease. The Boehringer Ingelheim Vaccine Assurance Program will then cover against the disease previously vaccinated against after one dose of the corresponding Boehringer Ingelheim vaccine. (See included charts for vaccines corresponding with covered diseases.) Vaccine protocols, including vaccination frequency, should be determined following a risk-based assessment by a veterinarian.
- A diagnosis of either equine influenza; equine herpesvirus (EHV-1 & EHV-4)*; Venezuelan, Eastern or Western encephalomyelitis; rabies, tetanus; or West Nile virus will be made following clinical signs of such diseases under universally accepted diagnostic methods, as determined by the reporting DVM and Boehringer Ingelheim Veterinary Technical Services.
- Coverage under the Boehringer Ingelheim Vaccine Assurance Program is limited to diagnostic and treatment costs for equine influenza; equine herpesvirus (EHV-1 & EHV-4)*; Venezuelan, Eastern or Western encephalomyelitis; tetanus; West Nile virus or rabies, and is limited to \$5,000 per animal.
- Coverage of the Boehringer Ingelheim Vaccine Assurance Program for a disease expires 365 days from time of last vaccination with a Boehringer Ingelheim vaccine designed to protect against that disease. (See inside for vaccines corresponding with covered diseases.)

THEARTOFHORSE.COM

*Boehringer Ingelheim Assurance Program covers respiratory form of EHV-1 & EHV-4.

IMRAB[®], RHINOMUNE[®], TETGUARD[®] and ULTRAFIL[®] are registered trademarks of Boehringer Ingelheim Animal Health USA Inc. CALVENZA[®] and VETERA[®] are registered trademarks of Boehringer Ingelheim Vetmedica GmbH, used under license. <u>©</u>2024 Boehringer Ingelheim Animal Health USA Inc., Duluth, GA All Rights Reserved. US-EQU-0301-2023



